Allogeneic CAR T follow-up Phase 1 ALLO-501 and initial Phase 1 ALLO-501A data in relapsed/refractory NHL will be presented at ASCO
In a research note to investors ahead of the next ALLO-501 update due on May 19, Stifel analyst Benjamin Burnett said he is bullish on Allogene Therapeutics’ (ALLO) upcoming data as he believes the company’s preconditioning strategy will help to overcome cell persistence challenges and enable a “Yescarta-like CR-rate.” If this is achieved, the analyst estimates the stock will trade into the mid-$40s. Goldman Sachs analyst Salveen Richter is also “constructive” on ALLO-501’s potential to disrupt the treatment paradigm, noting redosing could be an attractive lever to further deepen responses.
ALLO-501 UPDATE AT ASCO: Longer-term Phase 1 CAR T ALLO-501 data in relapsed/refractory non-Hodgkin lymphoma will be presented at ASCO – with abstract publication on May 19 – where investors look to the durability of the clinical profile in comparison to autologous CAR T treatments, Goldman Sachs analyst Salveen Ricther noted in a research note to investors ahead of the event. To see the rest of the story Click Here.